Direto Pharma is focused on quality, regulatory compliance and scientific support in supplying cannabis-derived products for medical use. Our work is built to meet the requirements of Anvisa Resolution RDC No. 660/2022, issued by the Brazilian Health Regulatory Agency, promoting responsible and traceable access.

We act as a bridge between clinical practice, regulation and access to treatment. Beyond making importation possible, we have built a process that connects physicians, patients and therapies with technical rigor and organization.

Our portfolio meets international standards and comes with technical documentation and Certificates of Analysis (CoA) that confirm each product's composition and compliance.

We also share technical knowledge, helping medical cannabis become part of clinical practice based on evidence, responsibility and well-defined criteria.

Direto Pharma is a point of connection between regulation, medical practice and access to treatment, running a process that demands precision, responsibility and consistency at every step.